Page 19 - Pharma Sector

IPCA Labs targets Rs 100 crore market with new diabetic foot ulcer drug

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Capital goods, pharma, auto sectors shine with strong profit growth in Q1

IT Services and FMCG companies reported a slight uptick in revenue growth in Q1FY25, but their growth remains in low single digits

Alembic Pharma gets approval from US FDA to market generic medication

Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market a generic product indicated for prophylaxis of deep vein thrombosis. The company has received approval from the US Food and Drug Administration (USFDA) to market Dabigatran Etexilate Capsules (110 mg), the drug firm said in a regulatory filing. Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. The approved product is therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals Inc's Pradaxa Capsules (110 mg). The company said it now has a cumulative total of 211 ANDA (abbreviated new drug application) approvals from the USFDA. Shares of the company on Tuesday closed 3.17 per cent down at Rs 1,076 apiece on the BSE.

Aurobindo Pharma Q1FY25 results: Net profit jumps 61% to Rs 919 cr

Aurobindo Pharma on Saturday said its consolidated net profit increased 61 per cent year on year to Rs 919 crore in the first quarter ended June 2024, aided by strong sales across markets. The Hyderabad-based drug maker had reported a net profit of Rs 571 crore in the April-June quarter of last fiscal. Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement. "We are pleased with our continued strong performance this quarter, with a significant top-line growth across all our business segments," Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy stated. The profitability was sustained by improved gross margins and operational efficiencies, while ramping up our recently commercialised plants, he added. "We are confident in our ability to achieve our growth targets for FY25," Reddy said.

Lincoln Pharma Q1FY25 results: Net profit jumps 24% to Rs 23.67cr

Drug maker Lincoln Pharmaceuticals on Thursday said its consolidated net profit jumped by 24.51 per cent to Rs 23.67 crore in the April-June quarter of 2024-25 compared to Rs 19.01 crore in the year-ago quarter. Total income of the Ahmedabad-bnased company rose by 10 per cent to Rs 157.69 crore in the quarter under review from Rs 143.31 crore in the first quarter of 2023-24. Its operating profit (EBITDA) rose by 16.65 per cent to Rs 33.14 crore in the quarter from Rs 28.41 crore in Q1FY24. Both domestic and export operations have shown robust growth and the company is confident to enhance profitability and margins going forward, the company said in a statement. With focused growth strategies and business expansion plans for value added products and expanding to newer markets, the company is targeting revenue of Rs 750 crore in FY26, it said in the earnings statement. Lincoln Pharmaceuticals shares closed 0.95 per cent down at Rs 652.75 on BSE.

AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr

AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024. The drug maker had reported a net profit of Rs 54 crore in the April-June quarter of last fiscal. Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing. "We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said. Shares of AstraZeneca Pharma on Thursday ended 6.77 per cent lower at Rs 6,613.40 apiece on the BSE.

JB Chemicals & Pharma Q1 results: Net profit jumps 25% to Rs 177 cr

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .

Separate marketing code: Medical devices industry welcomes govt's move

A separate marketing practices code has been a long-standing demand for medical devices. Currently, the industry has to comply with the marketing practices code for pharmaceuticals

Indian pharma market registers over 6% growth in July '24: Pharmarack

"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report

Caplin Point stock zooms over 5% on robust Q1 results; bottomline grows 20%

The surge in the stock price came after the company announced its June quarter of financial year 2025 (Q1FY25) results.

Novo Nordisk plans to introduce drug for sickle cell disease in 3-5 years

The company announced the plan to hire about 1,300 new employees by the end of 2026, as per the statement at a media briefing

Gland Pharma Q1 FY25 results: Net profit falls 26%, revenue rises 16%

The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition

Lupin Q1 Preview: Steady US sales, market share gains to boost profits

Brokerage estimates suggest that the pharma major is expected to see strong double-digit growth in the bottom line and single-digit growth in the top line year-on-year (YoY)

USFDA issues 3 observations to Gland Pharma Hyderabad Unit, stock down 6%

The inspection at the Hyderabad facility took place between July 25, 2024 and August 02, 2024.

Reading the vital signs: Pharma sector, the market's trusted antidote

The pharma index was the only healthy pulse amid Friday's market declines

Govt agencies conducting risk-based inspections of pharma units: Nadda

Over 400 drug manufacturing units, including MSMEs, inspected after high frequency of NQS reports

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

USFDA scrutiny delays generic drug approvals for major Indian pharma firms

Big Pharma companies Cipla, Sun Pharma, Aurobindo Pharma, Dr Reddy's, and Lupin face intense scrutiny from the US Food and Drug Administration (USFDA)

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.